Brought to you by 
AZ and Merck enter Lynparza alliance; Merck pays $1.6bn up front
18 Oct 2021
Executive Summary
AstraZeneca PLC and Merck & Co. Inc. agreed to co-develop and commercialize AZ’s poly ADP ribose (PARP) inhibitor Lynparza (olaparib) as a monotherapy and in combination with other compounds for various types of cancer. The deal also involves AZ’s Phase III MEK inhibitor selumetinib and the marketed immunotherapies Keytruda (pembrolizumab) (PD-1 antagonist sold by Merck) and Imfinzi (durvalumab) (PD-L1 antagonist sold by AZ).
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
AZ and Merck enter Lynparza alliance; Merck pays $1.6bn up front
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice